|1.||Saraiva, Juliana: 5 articles (04/2013 - 01/2005)|
|2.||da Silva Ferreira, Daniele: 4 articles (04/2013 - 02/2010)|
|3.||Bastos, Jairo Kenupp: 4 articles (04/2013 - 02/2010)|
|4.||de Albuquerque, Sérgio: 4 articles (04/2013 - 02/2010)|
|5.||Esperandim, Viviane Rodrigues: 4 articles (04/2013 - 02/2010)|
|6.||Cunha, Wilson Roberto: 2 articles (04/2013 - 01/2013)|
|7.||Ferreira, Maria-José U: 2 articles (05/2012 - 02/2010)|
|8.||Rezende, Karen Cristina Souza: 1 article (04/2013)|
|9.||e Silva, Márcio Luis Andrade: 1 article (04/2013)|
|10.||Sousa Rezende, Karen Cristina: 1 article (01/2013)|
|1.||Chagas Disease (American Trypanosomiasis)
02/01/2010 - "Thus, the developed microparticles seem to be a promising system for sustained release of (-)-hinokinin for treatment of Chagas disease."
01/01/2013 - "Therefore, (-)-cubebin and (-)-hinokinin are promising therapeutic agents and could be used in future clinical studies concerning treatment of the Chagas disease. "
02/01/2010 - "(-)-Hinokinin-loaded poly(D,L-lactide-co-glycolide) microparticles were prepared and characterized in order to protect (-)-hinokinin of biological interactions and promote its sustained release for treatment of Chagas disease. "
02/01/2010 - "(-)-Hinokinin-loaded poly(D,-lactide-co-glycolide) microparticles for Chagas disease."
08/01/2010 - "The reduction of parasitism tissue upon treatment with two lignano lactones, namely (-)- cubebin (CUB) and (-)-hinokinin (HNK), was evaluated in the chronic phase of Chagas' disease by quantifying the enzyme beta-galactosidase expressed by the CL B5 clone strain of Trypanosoma cruzi. "
01/01/2013 - "We determine whether (-)-cubebin and (-)-hinokinin could be used as alternative drugs for the treatment of parasitic infections by Trypanosoma cruzi. "
04/01/2013 - "In this context, this study aims to evaluate the in vivo therapeutic activity of dibenzylbutyrolactone lignans (-)-cubebin and (-)-hinokinin during the acute phase of infection by T. "
|3.||Lung Neoplasms (Lung Cancer)
02/01/2010 - "The lignans threo-4,4'-dihydroxy-3-methoxylignan, (-)-dihydroguaiaretic acid, 4'-hydroxy-3,3',4-trimethoxylignan, 3,3',4,4'-tetramethoxylignan, 4,4'-diacetyl-3,3'-dimethoxylignan, talaumidin, heliobuphthalmin, (-)-dihydro-cubebin, and hinokinin were evaluated for their ability to inhibit human cytomegalovirus (HCMV) IE-antigen expression in lung cancer cells (A549). "
|4.||Hepatocellular Carcinoma (Hepatoma)
05/01/2012 - "Seven lignans, previously isolated from Pycnanthus angolensis or obtained by derivatization, namely the dibenzylbutane-type lignans threo-4,4'-dihydroxy-3-methoxylignan (1), 4'-hydroxy-3,3',4-trimethoxylignan (2), (-)-dihydroguaiaretic acid (3), 3,3',4,4'-tetramethoxylignan (4), 4,4'-diacetyl-3,3'-dimethoxylignan (5), heliobuphthalmin (6) and the butyrolactone lignan hinokinin (7), were evaluted for their ability as apoptosis inducers in human hepatoma HuH-7 cells. "